GlassScriptPhysician profile
Maurie Patterson
NPI 1720020027
$3,348.82
in general payments reported to CMS, 2019-2025
19 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $54.66 · 2021: $168 · 2022: $381 · 2023: $479 · 2024: $786 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,283 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,283.38 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,360.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $572.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $418.76 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $277.10 | 2025 | Auvelity |
| Novo Nordisk INC | $121.03 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $120.02 | 2024-2025 | Veozah |
| Pfizer INC. | $95.31 | 2019-2025 | |
| Amgen INC. | $71.42 | 2019-2022 | |
| Glaxosmithkline, LLC. | $70.58 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Ardelyx, INC. | $64.59 | 2024-2025 | Ibsrela |
| Corcept Therapeutics | $30.83 | 2025 | Korlym |
| Avanir Pharmaceuticals, INC. | $28.91 | 2019 | |
| Dexcom, INC. | $25.97 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $21.95 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $19.34 | 2024 | Voquezna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $14.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.70 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.98 | 2020 | |
| Inogen, INC. | $6.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurie Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.